Table 3. Heparin rats.
| Heparin 10 mg/kg i.v. | Bleeding time | Amount of bleeding | PLT before | PLT after | HCT before | HCT after | PT | APTT | TT | FIB |
|---|---|---|---|---|---|---|---|---|---|---|
| Tail amputation | min | mL | x109/L | x109/L | L/L | L/L | ratio (PR) | ratio | sec | g/L |
| Control | >60 | 8.82± 2.2 | 654± 75 | 426± 105 | 0.448± 0.02 | 0.380+ 0.03 | 0.87±0.15 | 4.07± 1.21 | >150 | 1.5± 0.24 |
| BPC ug | 31± 8* | 5.08± 1.3* | 768± 93* | 600± 122* | 0.465± 0.03 | 0.439+ 0.03* | 0.91±0.17 | 2.46± 1.16* | 91± 14* | 1.6± 0.17 |
| BPC ng | 35± 9* | 5.45± 1.1* | 788± 88* | 611± 133* | 0.457± 0.03 | 0.434+ 0.04* | 0.93±0.20 | 2.00± 1.05* | 101± 21* | 1.5± 0.21 |
| L-arginine | >60 | 11.5± 3.4* | 784± 110* | 698± 51* | 0.426± 0.02 | 0.356± 0.03 | 0.33± 0.06 | >5.7 | >150 | 1.1± 0.20 |
| L-NAME | >60 | 8.0± 2.1 | 727± 80* | 479± 62 | 0.426± 0.04 | 0.380± 0.03 | 0.35± 0.08 | >5.7 | >150 | 1.2 ± 0.19 |
| L-NAME+ L-arginine | >60 | 8.10± 2.8 | 819± 79* | 498± 77 | 0.437± 0.03 | 0.411± 0.04 | 0.39±0.09 | >5.7 | >150 | 1.0± 0.15 |
| L-arginine+ BPC 157 ug | >60 | 7.3± 1.5* | 852± 130* | 721± 89* | 0.424± 0.04 | 0.338± 0.02 | 0.38±0.08 | >5.7 | >150 | 1.4± 0.16 |
| L-NAME+ BPC 157 ug | >60 | 5.5± 1.3* | 844± 155* | 601± 95* | 0.420± 0.03 | 0.364± 0.03 | 0.35±0.07 | >5.7 | >150 | 1.3± 0.16 |
| L-NAME+L-arginine+ BPC 157 ug | >60 | 5.1± 1.4* | 800± 129* | 658± 83* | 0.414± 0.05 | 0.381± 0.03 | 0.41±0.10 | >5.7 | >150 | 1.2± 0.16 |
Tail amputation, bleeding time, amount of bleeding, PLT, HCT, PT, APTT, TT, FIB values in heparin (10 mg/kg intravenously) challenged rats (10 rats at least per group) when treated with BPC 157 (10 μg/kg, 10 ng/kg), L-NAME (5 mg/kg), L-arginine (100 mg/kg) alone or combined, intravenously, immediately after intravenous heparin while controls received simultaneously an equivolume of saline (0.5 ml/kg intravenously). Mean ± SD,
*P<0.05 at least vs. control.